Guangdong Zhongsheng Pharmaceutical Overview
- Year Founded
-
1979
- Status
-
Public
- Employees
-
1,757
- Stock Symbol
-
002317
- Investments
-
7
- Share Price
-
$3.27
- (As of Friday Closing)
Guangdong Zhongsheng Pharmaceutical General Information
Description
Guangdong Zhongsheng Pharmaceutical Co Ltd is engaged in the pharmaceutical business. It is involved in the research and development, production and sales of pharmaceuticals, the cultivation of medicinal materials, and the processing of medicinal herbs, chemical raw material synthesis, and pharmaceutical trade.
Contact Information
Website
www.zspcl.comCorporate Office
- Information Industry Park, Xihu Industrial Zone
- Shilong Town
- Dongguan, Guangdong 523325
- China
Corporate Office
- Information Industry Park, Xihu Industrial Zone
- Shilong Town
- Dongguan, Guangdong 523325
- China
Guangdong Zhongsheng Pharmaceutical Stock Performance
As of 20-Nov-2026, Guangdong Zhongsheng Pharmaceutical’s stock price is $3.27. Its current market cap is $2.78B with 850M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.27 | $3.51 | $2.41 - $5.06 | $2.78B | 850M | 24.8M | $0.03 |
Guangdong Zhongsheng Pharmaceutical Financials Summary
As of 30-Sep-2026, Guangdong Zhongsheng Pharmaceutical has a trailing 12-month revenue of $305M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,900,433 | 2,213,820 | 1,250,467 | 1,774,875 |
| Revenue | 304,959 | 350,803 | 343,869 | 368,989 |
| EBITDA | 30,436 | 58,063 | (28,507) | 59,522 |
| Net Income | 29,271 | 38,346 | (41,692) | 37,212 |
| Total Assets | 765,039 | 733,138 | 760,742 | 911,114 |
| Total Debt | 35,482 | 46,636 | 113,194 | 102,221 |
Guangdong Zhongsheng Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Guangdong Zhongsheng Pharmaceutical Patents
Guangdong Zhongsheng Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026179803-A1 | Heterocyclic compound against respiratory syncytial virus and use thereof | Pending | 28-Feb-2025 | ||
| WO-2022237456-A1 | Use of 4-arylaminoquinazoline hydroxamic acid compounds in preparation of pain drug | Inactive | 12-May-2021 | ||
| WO-2021190337-A1 | Salt form and crystal form of compound as smo inhibitor, and preparation method therefor | Inactive | 27-Mar-2020 | ||
| WO-2021093733-A1 | Quality control method for carbocisteine raw material and formulation thereof, and use thereof | Inactive | 11-Nov-2019 | ||
| AU-2018361264-A1 | Salt form and crystal form of compound as fgfr4 inhibitor and preparation method thereof | Active | 01-Nov-2017 | A61P35/00 |
Guangdong Zhongsheng Pharmaceutical Signals
Guangdong Zhongsheng Pharmaceutical Investments & Acquisitions (7)
Guangdong Zhongsheng Pharmaceutical’s most recent deal was a Secondary Transaction - Private with Raynovent. The deal was made on 20-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Raynovent | 20-Sep-2026 | Secondary Transaction - Private | Drug Discovery | ||
| Raynovent | 01-Dec-2022 | Later Stage VC | Drug Discovery | ||
| QuadMedicine | 09-May-2022 | Later Stage VC | Drug Delivery | ||
| ZhenShiMing | 13-Dec-2021 | Secondary Transaction - Private | Pharmaceuticals | ||
| Raynovent | 15-Dec-2020 | Early Stage VC | Drug Discovery |
Guangdong Zhongsheng Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.73 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Guangdong Zhongsheng Pharmaceutical Exits (2)
Guangdong Zhongsheng Pharmaceutical’s most recent exit was on 09-May-2022 from QuadMedicine. The exit was categorized as with 8 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| QuadMedicine | 09-May-2022 | Completed |
|
||
| Xuancheng Eye Hospital | 14-Nov-2017 | Merger/Acquisition | Completed |
Guangdong Zhongsheng Pharmaceutical Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Raynovent | Guangzhou, China | 2018 | |
| Hubei Lingsheng Pharmaceutical Company | Xiangyang, China | 2010 |
Guangdong Zhongsheng Pharmaceutical FAQs
-
When was Guangdong Zhongsheng Pharmaceutical founded?
Guangdong Zhongsheng Pharmaceutical was founded in 1979.
-
Where is Guangdong Zhongsheng Pharmaceutical headquartered?
Guangdong Zhongsheng Pharmaceutical is headquartered in Dongguan, China.
-
What is the size of Guangdong Zhongsheng Pharmaceutical?
Guangdong Zhongsheng Pharmaceutical has 1,757 total employees.
-
What industry is Guangdong Zhongsheng Pharmaceutical in?
Guangdong Zhongsheng Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Guangdong Zhongsheng Pharmaceutical a private or public company?
Guangdong Zhongsheng Pharmaceutical is a Public company.
-
What is Guangdong Zhongsheng Pharmaceutical’s stock symbol?
The ticker symbol for Guangdong Zhongsheng Pharmaceutical is 002317.
-
What is the current stock price of Guangdong Zhongsheng Pharmaceutical?
As of 20-Nov-2026 the stock price of Guangdong Zhongsheng Pharmaceutical is $3.27.
-
What is the current market cap of Guangdong Zhongsheng Pharmaceutical?
The current market capitalization of Guangdong Zhongsheng Pharmaceutical is $2.78B.
-
What is Guangdong Zhongsheng Pharmaceutical’s current revenue?
The trailing twelve month revenue for Guangdong Zhongsheng Pharmaceutical is $305M.
-
What is Guangdong Zhongsheng Pharmaceutical’s annual earnings per share (EPS)?
Guangdong Zhongsheng Pharmaceutical’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process